Sab biotherapeutics announces 1-for-10 reverse stock split

Sioux falls, s.d., jan. 02, 2024 (globe newswire) -- sab biotherapeutics, inc. (nasdaq: sabs), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human anti-thymocyte immunoglobulin (higg) for disease-modification of type 1 diabetes (t1d), today announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. eastern time on january 5, 2024.
SABS Ratings Summary
SABS Quant Ranking